Duncan E. McRee, Ph.D., President is an internationally recognized leader in the field of protein crystallography. Prior to forming ActiveSight, Dr. McRee was Director of Crystallography at Syrrx where he helped develop automated, high throughput crystallographic methods to accelerate structure based drug design. Previously, Dr. McRee was a faculty member at The Scripps Research Institute where he ran an active program in determining metalloprotein structures by X-ray crystallography, including the first structure of a microsomal P450. Dr. McRee has over 90 entries in the PDB and has authored over 70 publications and the widely-used book “Practical Protein Crystallography.” He is the founder of Molecular Images, a crystallographic software company writing new software for a consortium of pharmaceutical companies that has been acquired by Rigaku Americas, and is an Adjunct Associate Professor of Molecular Biology at The Scripps Research Institute.

Vicki Nienaber, Ph.D., Chief Scientific Officer, is well known for her pioneering work in the utilization of X-ray crystallography and fragment-based screening for structure-based drug design. Vicki was most recently Senior Director of Lead Discovery and Crystallography at SGX Pharmaceuticals, where she ran the c-Abl kinase drug discovery project in collaboration with Novartis. While working at Abbott Laboratories, she was the lead inventor of fragment-based screening, co-inventor of the ACTOR^TM robotic system for automated crystal sample handling, and she developed one of the first automated structure-based drug design laboratories. Vicki has written numerous peer-reviewed scientific publications and is an author of four patents.

Ofir Moreno, Ph.D., Senior Director of Drug Discovery, has demonstrated broad expertise in the advancement of small-molecules from early discovery to clinical candidates, via extensive use of outsourcing. After initiating his career at Merck, he went on to earn his Ph.D. from Harvard University, and has since been involved in the initiation of small-molecule programs at Amgen, Corvas International and Dendreon Corporation, and has led two programs to clinical candidates. Most recently, he led a program from early discovery towards a clinical candidate almost entirely through outsourcing; he built the small-molecule infrastructure and outsourced medicinal chemistry as well as in vitro and in vivo pharmacology, where he was directly involved in experimental design and analysis of results. Building upon ActiveSight's core expertise in Structural Biology and Fragment Screening, Ofir's expertise enable us to perform Fragment-Based Drug Discovery, and take small-molecule programs to IND.

John Badger, Ph.D., Director of Structural Biology has many years of experience in structure-based drug discovery, computational crystallography and fragment-based screening. He is the author of our automated scripting which allows for rapid, automated structure solution. Previous to ActiveSight he ran the Automatic Structure Consortium which included several large pharmaceuticals as members. From 1999 to 2006 he worked at SGX where he gained experience in fragment-based screening and rapid structure determination.